Rhumbline Advisers Grows Position in Replimune Group, Inc. (NASDAQ:REPL)

Rhumbline Advisers increased its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL) by 8.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 95,465 shares of the company’s stock after purchasing an additional 7,317 shares during the quarter. Rhumbline Advisers owned 0.14% of Replimune Group worth $1,156,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Baker BROS. Advisors LP raised its stake in shares of Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after acquiring an additional 1,000,000 shares during the period. Braidwell LP raised its position in Replimune Group by 203.0% in the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock valued at $33,656,000 after purchasing an additional 2,057,460 shares during the period. State Street Corp lifted its stake in Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after purchasing an additional 1,182,181 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Replimune Group by 17.9% during the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after buying an additional 217,308 shares during the period. Finally, Parkman Healthcare Partners LLC grew its stake in shares of Replimune Group by 45.5% in the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock valued at $8,371,000 after buying an additional 238,747 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. increased their target price on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. HC Wainwright increased their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. BMO Capital Markets lifted their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Finally, Jefferies Financial Group upped their target price on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $19.43.

Insiders Place Their Bets

In other news, CEO Sushil Patel sold 10,000 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the transaction, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 8.80% of the stock is owned by company insiders.

Replimune Group Stock Up 2.2 %

REPL stock opened at $12.29 on Thursday. The company’s 50 day moving average price is $12.78 and its 200 day moving average price is $12.04. The firm has a market capitalization of $946.51 million, a price-to-earnings ratio of -4.00 and a beta of 1.30. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). On average, equities research analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.